On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...

(Reuters) -British pharmaceutical giant GSK said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for eligible patients in ...

Fluticasone propionate, salmeterol (as xinafoate); 45mcg/21mcg, 115mcg/21mcg, 230mcg/21mcg; per inh; metered-dose inhaler; CFC-free. Store at room temperature between 68° F and 77° F (20° C and 25° C) ...

A switch in Medicaid's formula could mean many children will go without inhalers in the coming months. The process change means drugmakers have to pay Medicaid if list prices on older products are ...

On November 18, 2005, FDA alerted health care professionals and patients that several long-acting bronchodilator medicines have been associated with possible increased risk of worsening wheezing ...

DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Advair" report has been added to ResearchAndMarkets.com's offering. Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose ...

March 20 (Reuters) - British pharmaceutical giant GSK said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for eligible ...